Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Tunisia: These 8 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Tunisia: These 8 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can ZYKADIA (ceritinib) generic drug versions launch in Tunisia?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Tunisia Patent 2,009,000,225
Patent Title: COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE KINASE INHIBITORS

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in Tunisia?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Tunisia Patent 2,009,000,347
Patent Title: DERIVES DE PLEUROMUTILINE POUR LE TRAITEMENT DE MALADIES TRANSMISES PAR DES MICROBES

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in Tunisia?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Tunisia Patent 2,009,000,447
Patent Title: AN EXTENTED-RELEASE COMPOSITION COMPRISING A SOMATOSTATIN DERIVATIVE IN MICROPARTICLES

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Tunisia?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Tunisia Patent 2,009,000,514
Patent Title: SALTS OF THE JANUS KINASE INHIBITOR (R) -3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can ENTRESTO SPRINKLE (sacubitril; valsartan) generic drug versions launch in Tunisia?

Generic name: sacubitril; valsartan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 11, 2027
Generic Entry Controlled by: Tunisia Patent SN07264
Patent Title: ORGANIC COMPOUNDS

Drug Price Trends for ENTRESTO SPRINKLE
ENTRESTO SPRINKLE is a drug marketed by Novartis. There are three patents protecting this drug. There has been litigation on patents covering ENTRESTO SPRINKLE

See drug price trends for ENTRESTO SPRINKLE.

The generic ingredient in ENTRESTO SPRINKLE is sacubitril; valsartan. Additional details are available on the sacubitril; valsartan profile page.

When can KAZANO (alogliptin benzoate; metformin hydrochloride) generic drug versions launch in Tunisia?

Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 19, 2027
Generic Entry Controlled by: Tunisia Patent 2,010,000,019
Patent Title: SOLID PREPARATION COMPRISING ALOGLIPTIN AND METFORMIN HYDROCHLORIDE

Drug Price Trends for KAZANO
KAZANO is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KAZANO

See drug price trends for KAZANO.

The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.

When can INTRAROSA (prasterone) generic drug versions launch in Tunisia?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: Tunisia Patent 2,010,000,065
Patent Title: DHEA COMPOSITIONS FOR TREATING MENOPAUSE

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Tunisia?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Tunisia Patent 2,010,000,152
Patent Title: PHARMACEUTICAL COMPOSITIONS

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

Tunisia Branded and Generic Drug Markets: Regulatory Opportunities, Patent Risks, and Market Access Assessment

Last updated: October 9, 2026

Tunisia has a mixed pharmaceutical market in which locally manufactured generics supply most routine medicines by volume, while imported branded products, specialty medicines, biologics, vaccines, and hospital products account for a disproportionate share of spending. The main commercial opportunities are local manufacturing, biosimilars, contract production, oncology, chronic-disease medicines, and exports to African markets. The main constraints are regulated pricing, foreign-exchange shortages, public-sector payment delays, centralized procurement, registration requirements, and limited market-access predictability.

What is the structure of Tunisia's branded and generic drug market?

Tunisia's market is divided between:

  1. Locally manufactured medicines, dominated by generic products.
  2. Imported originator and specialty medicines.
  3. Imported generics and active pharmaceutical ingredients.
  4. Hospital and public-sector products procured through the Pharmacy Central of Tunisia, or PCT.
  5. Retail pharmacy products distributed through wholesalers and private-sector channels.

Local industry is reported to cover approximately three-quarters of domestic medicine consumption by volume, although the domestic sector remains more dependent on imported active ingredients, excipients, packaging materials, and finished products for complex therapies. The imported segment has a higher value concentration because it includes oncology drugs, biologics, vaccines, orphan medicines, insulin, and other specialty products (FIPA-Tunisia, 2023; WHO, 2022).

Market segment Typical supply source Commercial characteristics
Chronic primary-care medicines Local manufacturers and imported generics High generic penetration; strong price sensitivity
Hospital medicines PCT procurement and local manufacturers Tender-driven; payment timing is a major risk
Specialty medicines Multinational companies and local distributors High import dependence; reimbursement and FX constraints
Biologics and biosimilars Mainly imported, with limited local capability Significant regulatory and manufacturing opportunity
Vaccines Imported products and selected local or regional supply Public-sector procurement and national-program demand
Consumer health products Local and multinational companies Less exposed to strict prescription reimbursement rules

The competitive market is therefore not a simple originator-versus-generic structure. A branded generic manufactured in Tunisia can compete effectively in primary-care categories, while multinational originators retain stronger positions in products with limited generic competition, complex manufacturing, patent protection, or strong physician familiarity.

Which companies compete in Tunisia's branded and generic drug market?

Tunisia has a substantial domestic manufacturing base, supported by local companies and subsidiaries or licensees of international pharmaceutical groups. The market includes:

  • Domestic generic manufacturers.
  • Multinational companies supplying imported originators.
  • Regional North African manufacturers.
  • Contract manufacturers producing under license.
  • Local marketing authorization holders representing foreign manufacturers.

Major commercial competition is concentrated in anti-infectives, cardiovascular medicines, diabetes therapies, gastrointestinal products, analgesics, respiratory products, and central nervous system medicines. Specialty competition is narrower because market entry requires stronger regulatory, pharmacovigilance, cold-chain, and reimbursement capabilities.

The local manufacturing sector benefits from government support for domestic production and import substitution. Companies with established Tunisian facilities or strong local partners generally have an advantage in public tenders, supply continuity, and price negotiations.

How does Tunisia regulate branded and generic medicines?

The Ministry of Health is the principal authority for pharmaceutical regulation. The Directorate of Pharmacy and Medicines, commonly known as the DPM, has historically handled registration, import authorization, quality review, pricing-related functions, and pharmaceutical oversight. Tunisia has also moved toward strengthening the institutional framework for a national medicines and pharmaceutical products agency.

A company generally must secure:

  • Marketing authorization.
  • An approved local pharmaceutical establishment or representative.
  • Product registration and technical documentation.
  • Good manufacturing practice evidence.
  • Import approvals where the product is not locally manufactured.
  • Pricing approval.
  • Pharmacovigilance compliance.
  • Batch-release and quality documentation for applicable products.

The regulatory file for a generic normally includes pharmaceutical quality data, bioequivalence or comparative evidence where required, manufacturing information, stability data, labeling, and evidence that the product complies with Tunisian requirements. Local administrative practice can differ according to product category, manufacturing site, therapeutic class, and whether the product is imported or locally produced.

What is the FDA regulatory status of medicines sold in Tunisia?

The U.S. Food and Drug Administration does not approve medicines for the Tunisian market. Tunisian authorization is granted under Tunisia's national regulatory system. FDA, EMA, or other foreign approvals can support the technical and quality assessment, but they do not replace the Tunisian marketing authorization process.

Foreign approvals can improve credibility for specialty products, vaccines, and biologics. They do not eliminate local requirements for registration, pricing, importation, pharmacovigilance, or supply-chain compliance.

How are generic medicines approved in Tunisia?

Generic entry is generally based on the applicant demonstrating pharmaceutical equivalence and, where applicable, bioequivalence to a reference product. The practical regulatory burden depends on:

  • Dosage form.
  • Active ingredient and therapeutic index.
  • Route of administration.
  • Availability of a recognized reference product.
  • Manufacturing site.
  • Whether the product is a complex formulation or biological medicine.
  • Local requirements for comparative dissolution, bioequivalence, and stability.

Conventional oral solid generics have the clearest entry pathway. The process is more demanding for:

  • Modified-release products.
  • Inhaled medicines.
  • Injectable products.
  • Long-acting formulations.
  • Transdermal systems.
  • Biosimilars.
  • Products with complex device components.

Generic companies can compete on price, supply reliability, local production, and tender performance. A low list price alone may not secure market access because product availability and public-sector procurement performance are important commercial variables.

What patent protections apply to medicines in Tunisia?

Tunisia's patent framework provides a 20-year patent term from the filing date, consistent with the Agreement on Trade-Related Aspects of Intellectual Property Rights. Pharmaceutical protection can cover:

  • Active pharmaceutical ingredients.
  • Polymorphs and crystalline forms.
  • Salts and solvates.
  • Formulations.
  • Dosage regimens.
  • Manufacturing processes.
  • New therapeutic uses, subject to national patentability standards.
  • Medical devices and drug-delivery systems.

A patent must be analyzed separately from regulatory approval. Registration of a generic does not necessarily establish freedom to launch if a valid Tunisian patent remains enforceable.

Tunisia's patent system does not operate as a direct equivalent of the U.S. Orange Book system. Publicly accessible, centralized listings that link every approved medicine to all relevant patents are limited. A company evaluating launch risk should conduct a Tunisian patent-register review, ownership review, validity assessment, and freedom-to-operate analysis.

Does Tunisia have an Orange Book for pharmaceutical patents?

Tunisia does not have a U.S.-style Orange Book that provides a comprehensive, authoritative linkage between approved products and enforceable patents. Patent information is primarily obtained through the Tunisian industrial property system and supporting regulatory and commercial records.

This creates several practical consequences:

  • Generic companies may receive less advance visibility into patent barriers.
  • Originators may have greater difficulty using patent information as an automatic regulatory blocking mechanism.
  • Patent clearance must be performed independently from product registration.
  • Formulation, process, and use patents can be overlooked if the review is limited to compound patents.

When do branded medicines lose exclusivity in Tunisia?

A medicine loses compound-patent exclusivity when the relevant Tunisian patent expires, is revoked, lapses, or is otherwise unenforceable. The effective commercial loss of exclusivity may occur later or earlier than patent expiry because market entry also depends on:

  • Generic registration timing.
  • Bioequivalence requirements.
  • Pricing approval.
  • Import authorization.
  • Availability of the reference product.
  • Public tender cycles.
  • Manufacturing capacity.
  • Patent litigation or settlement.
  • Regulatory exclusivity applicable to the product category.

Tunisia generally does not provide the same combination of pediatric exclusivity, orphan-drug exclusivity, and regulatory data exclusivity found in the United States or European Union. The precise treatment of undisclosed test data and regulatory reliance should be reviewed by product and filing date rather than assumed from the patent term.

Exclusivity element Tunisia market implication
Compound patent Usually the primary exclusivity barrier
Formulation patent Can delay or complicate specific dosage-form entry
Manufacturing-process patent May affect local production but not necessarily all alternative processes
Method-of-use patent Relevant if prescribing, labeling, or enforcement can be tied to the protected use
Regulatory data protection Less predictable and generally less extensive than U.S. or EU regimes
Pediatric exclusivity Not equivalent to the U.S. six-month extension
Patent-term extension No broad U.S.-style automatic extension framework should be assumed

What are the Paragraph IV and generic litigation risks in Tunisia?

Tunisia does not use the U.S. Paragraph IV certification system or the U.S. 30-month stay mechanism. A Tunisian generic applicant therefore does not normally follow the same notice-and-certification litigation pathway used for an ANDA in the United States.

Patent disputes may instead arise through:

  • Civil infringement proceedings.
  • Administrative challenges.
  • Customs actions.
  • Commercial injunctions.
  • Disputes over importation or distribution.
  • Challenges to patent validity or ownership.
  • Contract disputes involving licensed products.
  • Competition between local and imported versions.

The absence of a U.S.-style Paragraph IV mechanism does not eliminate litigation risk. It changes the timing and visibility of that risk. A generic company may need to complete an independent freedom-to-operate analysis before filing, registration, importation, or commercialization.

What patent litigation affects Tunisian drug launches?

Publicly visible information on Tunisian pharmaceutical patent litigation is less extensive than in the United States or Europe. This limits the reliability of market assessments based only on reported court cases. The most material disputes are likely to involve:

  • High-value originator products.
  • Imported specialty medicines.
  • Biologics and biosimilars.
  • Local manufacturing under license.
  • Formulations with narrow therapeutic windows.
  • Products with strong public-procurement demand.

Settlement agreements may include delayed entry, local manufacturing rights, licensing arrangements, supply agreements, or geographic restrictions. Their commercial effect depends on whether the settlement is enforceable in Tunisia and whether it covers the Tunisian market specifically.

What is the reimbursement and pricing environment in Tunisia?

Medicine prices are regulated, and price approval is a central commercial issue. The market includes public reimbursement through the National Health Insurance Fund, commonly known as CNAM, public procurement, and private retail sales.

Price and reimbursement decisions are influenced by:

  • Reference prices.
  • Therapeutic value.
  • International or regional price comparisons.
  • Local manufacturing status.
  • Public-health priorities.
  • Budget impact.
  • Generic alternatives.
  • Procurement conditions.

For generics, the price advantage can improve formulary access but also compress margins. Originators face significant pressure where multiple generic suppliers are present. Specialty products can encounter a different barrier: the issue is often not clinical demand but the ability of public institutions or patients to fund the product.

Public-sector payment delays and foreign-exchange restrictions can create working-capital exposure for manufacturers and distributors. These risks are particularly relevant for imported medicines, because the supplier may need to finance inventory before payment is received.

What regulatory opportunities exist for pharmaceutical companies in Tunisia?

Local manufacturing and technology transfer

The strongest opportunity is local production of medicines currently supplied through imports. Areas of interest include:

  • Oral solid generics.
  • Sterile injectables.
  • Oncology medicines.
  • Insulin and diabetes products.
  • Antibiotics.
  • Respiratory products.
  • Biosimilars.
  • Vaccines and vaccine components.
  • Active pharmaceutical ingredients.
  • Pharmaceutical packaging.

Local production can improve tender competitiveness, reduce import dependence, and support government objectives. It can also create a platform for exports to Algeria, Libya, Morocco, sub-Saharan Africa, and other markets where Tunisian regulatory or commercial relationships are established.

Contract manufacturing

International companies can use Tunisian manufacturers for:

  • Secondary manufacturing.
  • Packaging and labeling.
  • Regional supply.
  • Licensed generic production.
  • Technology transfer.
  • Public-sector tenders.
  • Export-oriented production.

The principal diligence issues are GMP compliance, inspection history, batch-release capability, quality agreements, intellectual-property controls, and supply-chain resilience.

Biosimilars and complex generics

Biosimilars remain a higher-value opportunity than standard oral generics because fewer local companies have the required development, analytical, clinical, and pharmacovigilance capabilities. Entry barriers include:

  • Reference-product access.
  • Comparability studies.
  • Cold-chain controls.
  • Immunogenicity monitoring.
  • Manufacturing validation.
  • Regulatory experience.
  • Reimbursement and physician acceptance.

Companies that establish local scientific and regulatory capabilities may gain an advantage as Tunisia seeks to control specialty-medicine expenditure.

Digital regulatory infrastructure

Electronic submissions, structured product information, electronic pharmacovigilance, and improved national databases could reduce administrative friction. Companies with strong regulatory operations, document control, and serialization capabilities may be better positioned as the regulatory system becomes more digitized.

What are the main regulatory and commercial challenges?

Challenge Effect on market entry
Registration complexity Delays launch and increases holding costs
Price controls Limits margin and weakens originator pricing power
Foreign-exchange constraints Can delay payment for imported products and APIs
Public-sector arrears Increases distributor and manufacturer working-capital exposure
Centralized procurement Concentrates customer risk in a small number of buyers
Import dependence Exposes supply to customs, currency, and logistics disruption
Limited patent transparency Increases freedom-to-operate uncertainty
Variable enforcement visibility Complicates litigation and settlement planning
Small domestic market May require export volume to justify manufacturing investment
Pharmacovigilance obligations Raises post-market compliance costs

The most significant structural risk is the mismatch between regulated prices and imported input costs. A manufacturer may receive approval but still find the product commercially unattractive if the authorized price does not support production, importation, quality testing, distribution, and working capital.

How does Tunisia compare with Morocco and Algeria?

Tunisia is attractive as a manufacturing and export base, but its market is smaller than Algeria's and operates under a different procurement and regulatory structure than Morocco's.

Factor Tunisia Morocco Algeria
Local manufacturing Established and export-oriented Large and diversified Significant, with strong localization policy
Generic competition High in primary care High and expanding High, with substantial local production
Public procurement PCT-centered Public tenders and institutional procurement Strong state and hospital procurement role
Regulatory predictability Improving, but administrative delays remain Generally viewed as comparatively structured Can involve substantial administrative and import constraints
Export potential Strong North Africa and Africa platform Strong regional and African platform More domestically focused, with export potential
Specialty access Constrained by reimbursement and imports Larger commercial opportunity Strong public-sector demand but access constraints
Patent transparency Limited compared with U.S. systems Requires local review Requires local review

Tunisia is most compelling for companies seeking a technically capable, cost-competitive production base with access to regional markets. It is less attractive for a pure import model that depends on premium pricing, fast payment, and unrestricted foreign-exchange access.

What generic launch scenarios exist in Tunisia?

Low-risk generic launch

A conventional oral generic with no active Tunisian patent barrier, available reference product, established bioequivalence pathway, and multiple local distributors can launch after registration and pricing approval. Competition will focus on price, availability, physician confidence, and tender access.

Moderate-risk launch

A product with a formulation patent, method-of-use patent, or uncertain patent ownership requires a targeted freedom-to-operate review. The generic may be registrable but commercially exposed if the originator obtains an injunction or pursues an infringement claim.

High-risk launch

A biosimilar, sterile injectable, complex inhalation product, or high-value oncology medicine faces combined regulatory, patent, manufacturing, procurement, and reimbursement risk. Local production or a strong licensed partnership may be necessary to achieve viable market access.

How strong is the pharmaceutical patent estate in Tunisia?

Patent strength is product-specific rather than market-wide. A strong estate generally has:

  • A valid compound patent.
  • Enforceable formulation or process claims.
  • Clear ownership and chain of title.
  • Remaining patent term.
  • Claims covering the commercially necessary product.
  • Evidence supporting validity against novelty and inventive-step attacks.
  • A realistic enforcement path in Tunisia.

A weak estate may rely only on expired compound claims, narrow formulation claims, poorly drafted use claims, or patents with uncertain local validity. Patent strength should be assessed separately from the originator's global portfolio because a U.S., European, or PCT patent does not automatically create enforceable rights in Tunisia.

Key Takeaways

  • Tunisia is a generic-heavy market with strong local manufacturing and continued dependence on imported APIs and specialty medicines.
  • Originator products retain value in oncology, biologics, vaccines, orphan medicines, and complex formulations.
  • The PCT is central to public-sector procurement and creates concentrated customer and payment exposure.
  • Tunisia does not use the U.S. Paragraph IV system or a comprehensive Orange Book.
  • Patent clearance requires an independent Tunisian review of compound, formulation, process, and use patents.
  • Local production, contract manufacturing, biosimilars, sterile products, oncology, and African exports offer the strongest growth opportunities.
  • Price regulation, foreign-exchange pressure, payment delays, registration timing, and limited patent transparency are the principal market risks.
  • Generic launch planning should combine regulatory approval, patent clearance, pricing analysis, procurement strategy, and supply-chain financing.

FAQs About Tunisia's Pharmaceutical Market

Is Tunisia favorable for generic drug manufacturing?

Yes. Tunisia has an established local manufacturing base, technical labor, domestic generic demand, and export potential. Project economics depend on pricing approval, API sourcing, procurement access, and export scale.

Can a generic be registered before a Tunisian patent expires?

Regulatory filing and commercial launch should be analyzed separately. A product may be technically registrable before patent expiry, but commercialization can create infringement exposure if a valid Tunisian patent covers the product, formulation, process, or use.

Are biosimilars commercially viable in Tunisia?

Biosimilars have potential because specialty-medicine budgets are constrained, but commercial viability depends on reference-product access, regulatory comparability requirements, reimbursement, physician acceptance, cold-chain capability, and public procurement.

Who imports medicines for Tunisia's public sector?

The Pharmacy Central of Tunisia is the principal public-sector procurement and distribution institution. Its role creates an important access channel but also concentrates tender, payment, and supply risks.

Does Tunisia grant the same pharmaceutical exclusivities as the United States?

No. Tunisia does not replicate the U.S. combination of Orange Book patent linkage, Paragraph IV litigation, pediatric exclusivity, and broad regulatory exclusivity. Patent and regulatory protections must be assessed under Tunisian law and administrative practice.

References

  1. Foreign Investment Promotion Agency Tunisia. (2023). Pharmaceutical industry in Tunisia. FIPA-Tunisia.

  2. Government of Tunisia. (2000). Law No. 2000-84 of August 24, 2000, relating to patents. Tunisian legal framework.

  3. Ministry of Health, Tunisia. (n.d.). Directorate of Pharmacy and Medicines: Pharmaceutical regulatory framework. Tunis, Tunisia.

  4. Pharmacy Central of Tunisia. (n.d.). Public pharmaceutical procurement and distribution information. Tunis, Tunisia.

  5. World Health Organization. (2022). The pharmaceutical sector and access to medicines in the Eastern Mediterranean Region. WHO Regional Office for the Eastern Mediterranean.

  6. World Trade Organization. (1994). Agreement on Trade-Related Aspects of Intellectual Property Rights. Marrakesh Agreement Establishing the World Trade Organization.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.